JP5557849B2 - カルバゾールおよびカルボリンキナーゼ阻害剤 - Google Patents
カルバゾールおよびカルボリンキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP5557849B2 JP5557849B2 JP2011542419A JP2011542419A JP5557849B2 JP 5557849 B2 JP5557849 B2 JP 5557849B2 JP 2011542419 A JP2011542419 A JP 2011542419A JP 2011542419 A JP2011542419 A JP 2011542419A JP 5557849 B2 JP5557849 B2 JP 5557849B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- mmol
- hydrogen
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C(C1)C2C*CC1C2 Chemical compound C(C1)C2C*CC1C2 0.000 description 16
- DXDCSKQEZNLXAI-UHFFFAOYSA-N C1C2OCC1[IH]OC2 Chemical compound C1C2OCC1[IH]OC2 DXDCSKQEZNLXAI-UHFFFAOYSA-N 0.000 description 1
- HIDRZGGMZNKARB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1ccc(c(cc(cc2C(N)=O)-c(cc3Cl)ccc3O)c2[nH]2)c2c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1ccc(c(cc(cc2C(N)=O)-c(cc3Cl)ccc3O)c2[nH]2)c2c1)=O HIDRZGGMZNKARB-UHFFFAOYSA-N 0.000 description 1
- VBAWBOKLBXJESF-UHFFFAOYSA-N CC(C)Nc(cc1)cc2c1c(nc(cc1C(N)=O)-c3cccc(C(F)(F)F)c3)c1[nH]2 Chemical compound CC(C)Nc(cc1)cc2c1c(nc(cc1C(N)=O)-c3cccc(C(F)(F)F)c3)c1[nH]2 VBAWBOKLBXJESF-UHFFFAOYSA-N 0.000 description 1
- PRUWVKZFXCDEML-UHFFFAOYSA-N CC(C)OC(c(cc1)cc2c1c(nc(cc1C(OC)=O)-c3ccccc3)c1[nH]2)=O Chemical compound CC(C)OC(c(cc1)cc2c1c(nc(cc1C(OC)=O)-c3ccccc3)c1[nH]2)=O PRUWVKZFXCDEML-UHFFFAOYSA-N 0.000 description 1
- JSSBODDKNWRASO-UHFFFAOYSA-N CCOC(c1c2[nH]c3cc(C(N4CCOCC4)=O)ccc3c2cc(-c2ccccc2)n1)=O Chemical compound CCOC(c1c2[nH]c3cc(C(N4CCOCC4)=O)ccc3c2cc(-c2ccccc2)n1)=O JSSBODDKNWRASO-UHFFFAOYSA-N 0.000 description 1
- MJLDMRDVPAZXDF-UHFFFAOYSA-O CCc1cc(-c(cc2C(N)=O)cc3c2[nH]c2cc(NCCNC(OC(C)(C)C)=O)ccc32)ccc1[OH2+] Chemical compound CCc1cc(-c(cc2C(N)=O)cc3c2[nH]c2cc(NCCNC(OC(C)(C)C)=O)ccc32)ccc1[OH2+] MJLDMRDVPAZXDF-UHFFFAOYSA-O 0.000 description 1
- XJFIXFALKHTPPU-UHFFFAOYSA-N CN(CC1)CCN1C(c1ccc2[nH]c(c(C([N-]#C)=O)cc(-c3cccc(OC)c3)c3)c3c2c1)=O Chemical compound CN(CC1)CCN1C(c1ccc2[nH]c(c(C([N-]#C)=O)cc(-c3cccc(OC)c3)c3)c3c2c1)=O XJFIXFALKHTPPU-UHFFFAOYSA-N 0.000 description 1
- NGXGOLOXHOLJNL-UHFFFAOYSA-N CNc(c(C=N)c1)ccc1-c(cc1C(N)=O)nc2c1[nH]c1c2ccc(N(CC2)CCC2N(C)C)c1 Chemical compound CNc(c(C=N)c1)ccc1-c(cc1C(N)=O)nc2c1[nH]c1c2ccc(N(CC2)CCC2N(C)C)c1 NGXGOLOXHOLJNL-UHFFFAOYSA-N 0.000 description 1
- LOCBGJIZVNCPLV-UHFFFAOYSA-N COC(c1c2[nH]c3cccc(OCc4ccccc4)c3c2nc(-c2ccccc2)c1)=O Chemical compound COC(c1c2[nH]c3cccc(OCc4ccccc4)c3c2nc(-c2ccccc2)c1)=O LOCBGJIZVNCPLV-UHFFFAOYSA-N 0.000 description 1
- LQGABZRZAFKBDP-UHFFFAOYSA-N COC(c1cc(-c(cc2)ccc2Cl)nc2c1[nH]c1c2ccc(OCCCN2CCOCC2)c1)O Chemical compound COC(c1cc(-c(cc2)ccc2Cl)nc2c1[nH]c1c2ccc(OCCCN2CCOCC2)c1)O LQGABZRZAFKBDP-UHFFFAOYSA-N 0.000 description 1
- GIDIODFDYAUKQP-UHFFFAOYSA-N COC(c1cc(Br)nc(-c2ccc(N3CCOCC3)nc2)c1N)=O Chemical compound COC(c1cc(Br)nc(-c2ccc(N3CCOCC3)nc2)c1N)=O GIDIODFDYAUKQP-UHFFFAOYSA-N 0.000 description 1
- BWLGZTBIHPYNMT-UHFFFAOYSA-N COc(cc1)cc(N)c1-c1cc(C(N)=O)cc(N2CCCCC2)n1 Chemical compound COc(cc1)cc(N)c1-c1cc(C(N)=O)cc(N2CCCCC2)n1 BWLGZTBIHPYNMT-UHFFFAOYSA-N 0.000 description 1
- AYLAGICKUGYWJC-UHFFFAOYSA-N COc(ccc(-c(cc1)cc(N)c1Nc1ccc(CO)cc1)c1)c1F Chemical compound COc(ccc(-c(cc1)cc(N)c1Nc1ccc(CO)cc1)c1)c1F AYLAGICKUGYWJC-UHFFFAOYSA-N 0.000 description 1
- NJCLJSZMPFXXBD-UHFFFAOYSA-N COc1cccc(-c(cc2)cc(C#N)c2Nc2ccncc2)c1 Chemical compound COc1cccc(-c(cc2)cc(C#N)c2Nc2ccncc2)c1 NJCLJSZMPFXXBD-UHFFFAOYSA-N 0.000 description 1
- DHHVBPMXGICWFW-UHFFFAOYSA-N NC(c1cc(-c(cc2Cl)ccc2O)cc2c1[nH]c1cc(N(CC3)CCS3(=O)=O)ccc21)=O Chemical compound NC(c1cc(-c(cc2Cl)ccc2O)cc2c1[nH]c1cc(N(CC3)CCS3(=O)=O)ccc21)=O DHHVBPMXGICWFW-UHFFFAOYSA-N 0.000 description 1
- YFTOZZUMNIPYGI-UHFFFAOYSA-N NC(c1cc(-c2ccc(CN3CCOCC3)[o]2)nc2c1[nH]c1c2ccc(N2CCOCC2)c1)=O Chemical compound NC(c1cc(-c2ccc(CN3CCOCC3)[o]2)nc2c1[nH]c1c2ccc(N2CCOCC2)c1)=O YFTOZZUMNIPYGI-UHFFFAOYSA-N 0.000 description 1
- NNMKZJNHZHUARS-UHFFFAOYSA-N NC(c1cc(-c2ccccc2)nc2c1[nH]c1c2ccc(C(N2CCOCC2)=O)c1)=O Chemical compound NC(c1cc(-c2ccccc2)nc2c1[nH]c1c2ccc(C(N2CCOCC2)=O)c1)=O NNMKZJNHZHUARS-UHFFFAOYSA-N 0.000 description 1
- OZPWUUZBAQGZOL-UHFFFAOYSA-N NC(c1cc(Br)nc2c1[nH]c1c2ccc(NC(COCCCl)=O)c1)=O Chemical compound NC(c1cc(Br)nc2c1[nH]c1c2ccc(NC(COCCCl)=O)c1)=O OZPWUUZBAQGZOL-UHFFFAOYSA-N 0.000 description 1
- RKBOWBWWLBJYNW-UHFFFAOYSA-N Oc1ccc2c(nc(cc3C(N=O)=O)Br)c3[nH]c2c1 Chemical compound Oc1ccc2c(nc(cc3C(N=O)=O)Br)c3[nH]c2c1 RKBOWBWWLBJYNW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13904208P | 2008-12-19 | 2008-12-19 | |
| US61/139,042 | 2008-12-19 | ||
| PCT/US2009/068394 WO2010080474A1 (en) | 2008-12-19 | 2009-12-17 | Carbazole and carboline kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512886A JP2012512886A (ja) | 2012-06-07 |
| JP2012512886A5 JP2012512886A5 (https=) | 2013-01-24 |
| JP5557849B2 true JP5557849B2 (ja) | 2014-07-23 |
Family
ID=41625988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542419A Expired - Fee Related JP5557849B2 (ja) | 2008-12-19 | 2009-12-17 | カルバゾールおよびカルボリンキナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8815840B2 (https=) |
| EP (1) | EP2370407B1 (https=) |
| JP (1) | JP5557849B2 (https=) |
| CN (1) | CN102325752B (https=) |
| ES (1) | ES2490867T3 (https=) |
| WO (1) | WO2010080474A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5487214B2 (ja) | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| JP5567137B2 (ja) | 2009-09-03 | 2014-08-06 | ブリストル−マイヤーズ スクイブ カンパニー | Jak2阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用 |
| CN105189488B (zh) * | 2013-02-27 | 2018-07-24 | 百时美施贵宝公司 | 用作溴区结构域抑制剂的咔唑化合物 |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| EP3016950B1 (en) * | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| US9914740B2 (en) * | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| ES2857848T3 (es) * | 2013-12-24 | 2021-09-29 | Bristol Myers Squibb Co | Compuestos tricíclicos como agentes antineoplásicos |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US20180022748A1 (en) * | 2015-02-02 | 2018-01-25 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| GB201512678D0 (en) * | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| KR102625861B1 (ko) * | 2016-06-28 | 2024-01-17 | 삼성디스플레이 주식회사 | 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| GB201809102D0 (en) * | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| CN114829350B (zh) * | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| CN113880836B (zh) * | 2021-10-18 | 2023-03-14 | 浙江中医药大学 | 1,5,8-三取代γ-咔啉类衍生物及其制备方法和应用 |
| EP4434968A4 (en) * | 2021-11-19 | 2025-10-22 | Nain Biotech Hangzhou Co Ltd | TETRAHYDROCARBAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532261A (en) * | 1994-12-12 | 1996-07-02 | Merck & Co., Inc. | Carbapenem antibiotics, compositions containing such compounds and methods of use |
| WO2005067546A2 (en) * | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| NZ563687A (en) * | 2005-06-30 | 2011-07-29 | Smithkline Beecham Corp | 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta) |
| US8518964B2 (en) * | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| US20080293802A1 (en) * | 2005-12-16 | 2008-11-27 | Smithline Beecham Corporation | Chemical Compounds |
-
2009
- 2009-12-17 US US13/140,184 patent/US8815840B2/en active Active
- 2009-12-17 JP JP2011542419A patent/JP5557849B2/ja not_active Expired - Fee Related
- 2009-12-17 CN CN200980157175.0A patent/CN102325752B/zh not_active Expired - Fee Related
- 2009-12-17 EP EP09793679.3A patent/EP2370407B1/en not_active Not-in-force
- 2009-12-17 ES ES09793679.3T patent/ES2490867T3/es active Active
- 2009-12-17 WO PCT/US2009/068394 patent/WO2010080474A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20120058988A1 (en) | 2012-03-08 |
| ES2490867T3 (es) | 2014-09-04 |
| WO2010080474A1 (en) | 2010-07-15 |
| JP2012512886A (ja) | 2012-06-07 |
| CN102325752A (zh) | 2012-01-18 |
| EP2370407B1 (en) | 2014-06-18 |
| EP2370407A1 (en) | 2011-10-05 |
| CN102325752B (zh) | 2015-02-04 |
| US8815840B2 (en) | 2014-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5557849B2 (ja) | カルバゾールおよびカルボリンキナーゼ阻害剤 | |
| AU2008225766B2 (en) | Organic compounds and their uses | |
| CN102762549B (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| EP2066673B1 (en) | Tricyclic compounds and its use as tyrosine kinase modulators | |
| TWI471326B (zh) | 作為cFMS抑制劑之經取代之N-(1H-吲唑-4-基)咪唑[1,2-a]吡啶-3-羧醯胺化合物 | |
| KR101936851B1 (ko) | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 | |
| JP5592890B2 (ja) | ピロロトリアジンキナーゼ阻害剤 | |
| JP4795237B2 (ja) | N−置換ピラゾリル−アミジル−ベンズイミダゾリルc−Kit阻害剤 | |
| WO2019037678A1 (zh) | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 | |
| AU2007263017A1 (en) | Pyridine and pyrazine derivatives as MNK kinase inhibitors | |
| KR20150059647A (ko) | 키나제 억제제로서 유용한 이미다조트리아진카르보니트릴 | |
| WO2012019426A1 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| KR20120061951A (ko) | Jak2 억제제, 및 골수증식성 질환 및 암의 치료를 위한 그의 용도 | |
| BRPI0708615A2 (pt) | compostos de pirazol heterobicìclicos e métodos de uso | |
| CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| TW202400601A (zh) | 作為parp抑製劑的取代的三環類化合物及其用途 | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 | |
| JP2007502822A (ja) | c−Kit阻害剤としてのN3−置換イミダゾピリジン誘導体 | |
| CN111918863B (zh) | 杂环化合物 | |
| CN121079086A (zh) | DNA聚合酶θ抑制剂 | |
| WO2021092525A1 (en) | Wdr5 inhibitors and modulators | |
| CN113461670B (zh) | 作为转染期间重排激酶抑制剂的新的化合物 | |
| CN112300154B (zh) | 一类含氮杂环化合物、其制备方法和用途 | |
| CN114133394B (zh) | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 | |
| KR102650856B1 (ko) | 신규한 인다졸 유도체 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140401 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140603 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5557849 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |